United Kingdom (UK)
Recombinant monoclonal antibody to IGF1R. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 10H5.
UniProt Accession Number of Target Protein: P08069
Alternative Name(s) of Target: CD221; IGF1 receptor; Insulin-like growth factor 1 receptor; type I IGF receptor; Insulin-like growth factor I receptor; IGF-I receptor
Immunogen: The original antibody was generated from BALB/c mice hyperimmunized with human IGF-IR extracellular domain (amino acids 1-902) in Ribi adjuvant. Later on the humanized version was created by grafting the hypervariable regions onto human framework regions.
Specificity: This antibody binds the extracellular domain of the human and cynomolgus monkey insulin-like growth factor and effective blocks ligand (IGF-I and IGF-II)-receptor (IGF-IR) interaction. This antibody does not bind mouse or rodent IGF-1R.
Application Notes: The orginal humanized IgG1 version of this antibody binds human IGF-1R with an affinity of 1.1 nM in an ELISA. The binding specificity was also comfirmed using fluorescence activated cell sorting of IGF-IR-expressing MCF7 cells. This antibody was also used for the immunoprecipitaion of MCF7 cells. The original antibody inhibits IGF-IR-mediated signaling by blocking IGF-I and IGF-II binding and by inducing cell surface receptor downregulation via internalization and degradation, with the extracellular and intracellular domains of IGF-IR being differentially affected by the proteasomal and lysosomal inhibitors. In vitro, h10H5 exhibits antiproliferative effects on cancer cell lines. In vivo, h10H5 shows single-agent antitumor efficacy in human SK-N-AS neuroblastoma and SW527 breast cancer xenograft models and even greater efficacy in combination with the chemotherapeutic agent docetaxel or an anti–vascular endothelial growth factor antibody (PMID:18790743).
Antibody first published in:
Shang et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake. Mol Cancer Ther. 2008 Sep;7(9):2599-608. PMID:18790743
Note on publication:
Describes the generation, in vitro and in vivo characterization of this antibody.